| Literature DB >> 28893198 |
Lander Willem1, Frederik Verelst2, Joke Bilcke2, Niel Hens2,3, Philippe Beutels2,4.
Abstract
BACKGROUND: Individual-based models (IBMs) are useful to simulate events subject to stochasticity and/or heterogeneity, and have become well established to model the potential (re)emergence of pathogens (e.g., pandemic influenza, bioterrorism). Individual heterogeneity at the host and pathogen level is increasingly documented to influence transmission of endemic diseases and it is well understood that the final stages of elimination strategies for vaccine-preventable childhood diseases (e.g., polio, measles) are subject to stochasticity. Even so it appears IBMs for both these phenomena are not well established. We review a decade of IBM publications aiming to obtain insights in their advantages, pitfalls and rationale for use and to make recommendations facilitating knowledge transfer within and across disciplines.Entities:
Keywords: Agent-based; Dynamics; Emerging diseases; Endemic diseases; Individual-based; Mathematical epidemiology; Modeling; Networks; ODD protocol; Transmission
Mesh:
Substances:
Year: 2017 PMID: 28893198 PMCID: PMC5594572 DOI: 10.1186/s12879-017-2699-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1IBM studies published over time by topic (top) and purpose (bottom)
Characteristics of IBMs studies for infectious disease transmission published from 2006 to 2015
| Topic | Count | Purpose | Strategy | Economic | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pathogen | Type | Methods | Dynamics | Interventions | Vaccine | NPI | Drugs | Screening | Analysis | |
| Unspecified Close-contact | General | 186 | 95 | 77 | 14 | 5 | 9 | 1 | - | 4 |
| Unspecified STI | General | 9 | 3 | 5 | 1 | 1 | 1 | - | 1 | - |
| Unspecified Vector-borne | General | 7 | 7 | - | - | - | - | - | - | - |
| Bioterrorism | General | 6 | 3 | 1 | 2 | - | 2 | 1 | - | 1 |
| Influenza | Viral | 161 | 51 | 37 | 73 | 37 | 47 | 24 | 3 | 14 |
| HIV | Viral | 91 | 25 | 25 | 41 | 3 | 12 | 25 | 15 | 23 |
| HPV | Viral | 27 | 2 | 2 | 23 | 23 | - | - | 7 | 15 |
| Hepatitis C | Viral | 12 | 2 | 3 | 7 | 1 | - | 6 | 2 | 3 |
| Ebola | Viral | 8 | - | 5 | 3 | 1 | 3 | 2 | - | - |
| SARS | Viral | 8 | 4 | 3 | 1 | 1 | - | - | 1 | - |
| Smallpox | Viral | 7 | - | - | 7 | 7 | 3 | - | 3 | - |
| Measles | Viral | 5 | 1 | 1 | 3 | 3 | - | - | 1 | - |
| Polio | Viral | 4 | 1 | 2 | 1 | 1 | - | - | - | - |
| HIV+Hepatitis C | Viral | 3 | 1 | 1 | 1 | - | 1 | - | - | - |
| HIV+HSV | Viral | 3 | - | 1 | 2 | 1 | - | 1 | - | 1 |
| Varicella Zoster | Viral | 3 | 1 | 2 | - | - | - | - | - | - |
| Respiratory syncytial virus | Viral | 2 | - | - | 2 | 2 | - | - | - | 1 |
| Acute hemorrhagic conjunctivitis | Viral | 2 | 2 | - | - | - | - | - | - | - |
| Hepatitis A | Viral | 1 | - | - | 1 | 1 | 3 | - | - | - |
| Norovirus | Viral | 1 | - | 1 | - | - | - | - | - | - |
| Malaria | Vector-borne | 35 | 7 | 5 | 23 | 7 | 1- | 11 | 3 | 5 |
| Dengue | Vector-borne | 13 | 4 | 5 | 4 | 2 | 3 | - | - | - |
| Chikungunya | Vector-borne | 1 | - | - | 1 | - | 1 | - | - | - |
| Schistosoma | Parasitic | 3 | 2 | 1 | - | - | - | - | - | - |
| Wuchereria | Parasitic | 3 | 2 | - | 1 | - | 1 | 1 | - | - |
| Helminths | Parasitic | 2 | - | 1 | 1 | - | - | 1 | - | - |
| Onchocerca | Parasitic | 2 | - | - | 2 | - | - | 2 | - | 1 |
| Chagas disease | Parasitic | 1 | 1 | - | - | - | - | - | - | - |
| Toxocara | Parasitic | 1 | - | 1 | - | - | - | - | - | - |
| Cryptosporidium | Parasitic | 1 | 1 | - | - | - | - | - | - | - |
| Tuberculosis | Bacterial | 26 | 8 | 6 | 12 | - | - | 9 | 9 | 4 |
| MRSA | Bacterial | 14 | 3 | 2 | 9 | - | 13 | 2 | 4 | 1 |
| Chlamydia | Bacterial | 7 | 3 | - | 4 | 1 | - | - | 3 | 1 |
| Nosocomial infections | Bacterial | 7 | 3 | 2 | 2 | 1 | 4 | - | - | - |
| Syphilis | Bacterial | 6 | - | - | 6 | - | 2 | 1 | 4 | 1 |
| Pneumococcus | Bacterial | 5 | 1 | 1 | 3 | 2 | 1 | - | - | - |
| Cholera | Bacterial | 4 | - | 4 | - | - | - | - | - | - |
| Lepra | Bacterial | 4 | - | 2 | 2 | 1 | - | 2 | 1 | - |
| Gonorrhoea | Bacterial | 3 | - | 1 | 2 | 1 | - | - | 1 | - |
| Clostridium difficile | bacterial | 3 | - | - | 3 | - | 7 | 2 | 2 | - |
| Pertussis | bacterial | 3 | - | 1 | 2 | 2 | - | - | - | 1 |
| Meningococcus | bacterial | 3 | 1 | 1 | 1 | 1 | - | - | - | - |
| Acinetobacter baumannii | bacterial | 1 | - | - | 1 | - | 2 | - | - | - |
| Enterococcus | bacterial | 1 | - | 1 | - | - | - | - | - | - |
| Typhoid | bacterial | 1 | - | 1 | - | - | - | - | - | - |
| Mycobacterium ulcerans | bacterial | 1 | - | 1 | - | - | - | - | - | 1 |
| Foot and mouth disease | zoonose | 1 | 1 | - | - | - | - | - | - | - |
| Total | 698 | 235 | 202 | 261 | 105 | 125 | 91 | 60 | 77 | |
Each study was assigned one purpose, which is cumulative from methods, dynamics to intervention (e.g., studies about interventions can also describe dynamics and methods). The category “NPI” includes all non-pharmaceutical intervention strategies such as social distancing, school closure and improving standards of living and (hand-)hygiene. HIV: human immunodeficiency virus, HPV: human papillomavirus, HSV: herpes simplex virus, MRSA: methicillin-resistant S. aureus, STI: sexually transmitted infection
Terminology in abstract, title and keywords from all unique query hits and in the included IBM modeling studies for infectious disease transmission. One article can contain several terms
| All hits | Included articles | Positive predicted value | Sensitivity | |
|---|---|---|---|---|
| Model* | 5271 | 686 | 0.130 | 0.983 |
| Simulat* | 2318 | 504 | 0.217 | 0.722 |
| Agent-based | 969 | 251 | 0.259 | 0.360 |
| Individual-based | 616 | 241 | 0.391 | 0.345 |
| Micro-simulation | 396 | 54 | 0.136 | 0.077 |
| Cel* automata | 249 | 62 | 0.249 | 0.089 |
| Other individual-level related terms (see | 3367 | 124 | 0.037 | 0.178 |
| Disease | 2791 | 445 | 0.159 | 0.638 |
| Infect* | 1939 | 553 | 0.285 | 0.792 |
| Transmi* | 1847 | 441 | 0.239 | 0.632 |
| Epidem* | 3029 | 521 | 0.172 | 0.746 |
| Disease OR infect* | 3564 | 629 | 0.176 | 0.901 |
| Infect* AND disease AND transmi* | 628 | 252 | 0.401 | 0.361 |
| TOTAL | 5520 | 698 | 0.126 | 1.000 |
The asterisk (*) is used in the search as a wildcard and represents any group of characters, including no character
Design of IBM studies on vaccine-preventable childhood diseases, excluding influenza
| Reference | Topic, setting | Purpose | State variables | Population | Time horizon, step size | Realiza-tions | Platform | Reason IBM | Terminology |
|---|---|---|---|---|---|---|---|---|---|
| Grais et al. [ | Measles, Niger | Reactive vaccination | Age, social mixing patterns, location | 346.254 people | 1 year, per day | 1.000x | - | Spatio-temporal interventions and coverage | IBM |
| Perez and Dragicevic [ | Measles, Canada | Dynamics in spatial context | Social mixing patterns | 1.000 people | 60 days, per hour | 1x | RepastS | Spatio-temporal analysis | ABM |
| Liu et al. [ | Measles, USA | Reactive vaccination and contact tracing | Age, social mixing patterns, compliance | 118.261 people | 1 year, per day | 256x | C++ (FRED) | Contact tracing and clustering | ABM |
| Marguta and Parisi [ | Measles, UK | Dynamics using detailed mobility patterns | Preferred locations | “British Isles” | 60 years, per day | 100x | - | Mobility patterns | IBM |
| Thompson and Kisjes [ | Measles, USA Amish | Outbreak response in connected under-vaccinated subpopulations | Age, gender, social mixing patterns, conservatism, compliance | 280.000 people (dynamic) | 1 year, per 30 min | 1000x | Netlogo | Clustering | IBM |
| Martinez et al. [ | Meningococcus, Grid | Dynamics with immunity | Network location | 1.000 people (static) | 60 days, per day | 1x | Mathe-matica | Spatio-temporal analysis | CA |
| Pérez-Breva et al. [ | Meningococcus, Spain | Vaccination | Age, serotype | 1 million people (dynamic) | 36 years, per month | - | - | Serotype dynamics with spatial analysis | ABM |
| Poore and Bauch [ | Meningococcus, Canada | Vaccination and serotype groups | Age, serotype | - (dynamic) | 300 years, per month | 50x | - | Serotype dynamics with spatial analysis | ABM |
| Monteiro et al. [ | Varicella, USA | Dynamics and parameter fitting | Network position, neighbors | 1 million people | 11 years, per month | - | - | Spatio-temporal analysis | CA |
| Silhol and Boëlle [ | Varicella, Corsica | Dynamics and parameter fitting | Age, social mixing patterns | 35.000 children (dynamic) | 100 years, per day | 500x | - | Spatio-temporal analysis with clustering | ABM, IBM |
| Ogunjimi et al. [ | Varicella, Belgium | Dynamics and parameter fitting | Age, cellular mediated immunity | 998.400 people (dynamic) | 320 years, per week | 3x | MATLAB | Within-host cellular immunity | IBM |
| Ajelli and Merler [ | Hepatitis A, Italy | Household dynamics, vaccination, NPI | Age, social mixing patterns | 5.701.931 people (dynamic) | 50 years, per week | - | - | Clustering and assessment of real-world interventions | IBM |
| Karlsson et al. [ | Pneumococcus, Sweden | NPI | Age, social mixing patterns | 25.000 people | 15 years, per week | 100x | MATLAB | Spatio-temporal analysis | IBM |
| Saito et al. [ | Pneumococcus, Grid | Dynamics with antibiotics | Network location, social mixing behavior | 2.500 people | 400 days, per day | 100x | - | Spatio-temporal analysis | CA |
| Choi et al. [ | Pneumococcus, UK | Vaccination | Serotype | 48 million people (dynamic) | 20 years, per week | 10x | MATLAB | Serotype dynamics with spatial analysis | IBM |
| Flasche et al. [ | Pneumococcus, UK | Vaccination | Age, serotype | 243.792 people (dynamic) | 30 years, per day | - | C++ (on request) | Serotype dynamics with spatial analysis | IBM |
| Nurhonen et al. [ | Pneumococcus, Finland | Vaccination and serotype replacement | Age, social mixing patterns, serotype | 100.000 people (dynamic) | 100 years, per day | 50x | C++ | Serotype dynamics with spatial analysis | ABM, IBM, micro-simulation |
| Rahmandad et al. [ | Polio, Low-income country | Dynamics | Age, social mixing patterns | 100.000 people (dynamic) | 2000 days, per day | 1000x | AnyLogic | Spatio-temporal analysis | ABM, IBM |
| Kisjes et al. [ | Polio, USA Amish | Dynamics in connected under-vaccinated subpopulations | Age, gender, social mixing patterns | 276.000 people (dynamic) | 3 years, per 30 min | 1000x | Netlogo | Clustering | IBM |
| Wagner et al. [ | Polio, Nigeria | Expanded age group vaccination programs | Age, gender, risk factors | 300.000 people (dynamic) | 40 years, event-driven | - | C++ (EMOD) | Spatio-temporal risk factors | IBM |
| Kim and Rho [ | Polio (vaccine-derived), Grid | Dynamics with immunity and vaccine-related side effects | Network location | 100.000 people | 25 years, per day | 100x | - | Spatio-temporal analysis | IBM |
| Greer and Fisman [ | Pertussis, USA | Booster vaccination programs in hospital setting | Social mixing behavior | 38 patients with health care workers and family | 3 month, per day | 1000x | AnyLogic | Spatio-temporal analysis | ABM |
| de Vries et al. [ | Pertussis, The Netherlands | Universal booster vaccination programs | Age | 150.000 people (dynamic) | 25 years, event-driven | 20x | Arena | Individual stochastic disease burden | IBM |
| Sanstead et al. [ | Pertussis, USA | Dynamics | Age | 400.000 people | -, per day | 100x | NetLogo | Within-host dynamics with spatial analysis | ABM |
Studies are listed by topic. The state variables express the individual heterogeneity next to health-states (e.g., SIR, SIRV,... etc.). If multiple experiments are described, the maximal time horizon, minimal step size and maximum number of realizations are presented. A “dynamic population” considers next to health state also socio-demographical changes over time, such as aging and household alterations. NPI: all non-pharmaceutical intervention strategies, “-”: unknown